Data/hora: 11/06/2024 01:44:59

Provedor de dados: | 60
País: | Brazil
Título: | Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
Autores: | Liu,Lun-Fei; Chen,Ji-Su; Shen,Ji-Yang; Dou,Ting-Ting; Zhou,Jiong; Cai,Sui-Qing; Zheng,Min.
Data: | 2018-01-01
Ano: | 2018
Palavras-chave: | Psoriasis; Ustekinumab/efficacy; Biologic agents.
Resumo: | Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a fully human monoclonal antibody targeting the p40 subunit of both IL-12 and IL-23, has proven to be efficient and safe for treating patients with psoriasis. Yet, there have been no reports with human skin/blood samples that would elucidate the molecular mechanisms by which ustekinumab calms psoriasis skin lesions. To investigate the efficacy and molecular pathway (RORC, t-BOX and GATA) of ustekinumab in treating patients with psoriasis skin lesions. A total of 30 patients with psoriasis were randomized into placebo group and treatment group. PASI of each patient was calculated at 0, 12 and 24 weeks post-treatment. The mRNA levels of RORC, t-BOX and GATA in peripheral blood mononuclear cells separated from patients’ whole blood were analyzed using qPCR. Decreased mRNA of RORC, t-BOX and GATA were observed after continuous injections, indicating that ustekinumab exerts its effect by interacting with these molecules; while no significant difference in foxp3 mRNA levels were found between placebo group and treatment group.
Tipo: | Info:eu-repo/semantics/article
Idioma: | Inglês
Identificador: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000400615
Editor: | Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
Relação: | 10.1590/s2175-97902018000417349
Formato: | text/html
Fonte: | Brazilian Journal of Pharmaceutical Sciences  v.54 n.4 2018
Fonte: | info:eu-repo/semantics/openAccess